Analyst Ratings February 17, 2026

Citizens Sticks With Outperform on AMN Healthcare, Cites Signs of Staffing Market Stabilization

Analyst maintains $22 target as governance and guidance updates from AMN accompany divergent broker views

By Caleb Monroe AMN
Citizens Sticks With Outperform on AMN Healthcare, Cites Signs of Staffing Market Stabilization
AMN

Citizens reiterated its Market Outperform rating on AMN Healthcare Services and kept a $22.00 price objective, pointing to signs that the healthcare staffing market may be stabilizing and noting recent company commentary and a mid-term growth framework. The stock has traded down sharply in the last week even as other brokers adjust targets and the company updates its board and bylaws.

Key Points

  • Citizens reaffirmed a Market Outperform rating on AMN with a $22.00 price target while maintaining its revenue projections.
  • AMN shares have fallen over 20% in the past week and are trading at $16.25 despite a low revenue multiple.
  • BMO Capital raised its price target to $25 and kept an Outperform rating after management’s competitor-conference presentation; Citizens cited a tempered margin outlook for 2026-2027 when setting its $22 target.

Citizens has reaffirmed a Market Outperform rating for AMN Healthcare Services with a $22.00 price target, maintaining its positive stance despite recent share-price weakness. The stock is trading at $16.25 and has declined by more than 20% over the past week, a drop Citizens notes has occurred even though AMN is trading at a relatively low revenue multiple.

In its research note, Citizens points to signs that the broader healthcare staffing industry is moving toward stabilization after multiple years of secular decline. The firm says AMN has provided encouraging commentary about that possible stabilization, and the company has also outlined an intermediate-term growth algorithm that Citizens referenced in keeping its view on the shares.

Citizens analyst Constantine Davides maintained both the Market Outperform rating and the $22.00 price target on AMN. At the same time, Citizens acknowledged a more tempered margin outlook for 2026 and 2027, which informed the $22 target level; Citizens did not change its revenue projections for those years.

The broker-dealer landscape shows some divergence. BMO Capital lifted its price target on AMN to $25 and kept an Outperform rating after management presented at a competitor conference. According to BMO, that presentation laid out expectations for 2026 and beyond and emphasized revenue growth driven by a normalized fourth-quarter 2025 run rate. Citizens, by contrast, moved to a lower price target of $22 on a more cautious view of margins even as it left revenue assumptions intact.

Separately, AMN announced a planned change to its board. Director R. Jeffrey Harris will retire and will not stand for re-election at the 2026 annual meeting. The company said it intends to nominate Eric Palmer, an executive with more than 25 years of experience in healthcare services, for election to the board.

AMN also updated its corporate bylaws to conform with recent changes in Delaware law. The amendment affects procedures for shareholder meetings and director nominations, and the company framed the moves as part of ongoing strategic and governance adjustments.

Additional market commentary included a note that, per InvestingPro, AMN appears undervalued based on its Fair Value estimate.


Context and implications

Citizens' retention of an Outperform rating and a $22.00 target comes against a backdrop of volatile share performance and differing broker estimates. The firm highlighted potential stabilization in staffing demand and reiterated that the company set out an intermediate-term growth algorithm. Management disclosures, board changes, and bylaw updates were also cited as part of AMN’s recent corporate activity.

Risks

  • Near-term margin pressure - Citizens cited a tempered margin outlook for 2026 and 2027, which could affect profitability projections and investor returns; this primarily impacts the healthcare staffing sector and related service providers.
  • Share-price volatility - AMN’s more than 20% decline in the prior week demonstrates elevated market risk for equity holders, affecting investor sentiment in healthcare and staffing equities.
  • Governance and board transitions - The planned retirement of director R. Jeffrey Harris and nomination of Eric Palmer introduce short-term uncertainty around board composition and oversight, which can influence corporate strategy and investor confidence.

More from Analyst Ratings

DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 BWS Financial Boosts A10 Networks Price Target Citing AI-Driven Network Traffic Feb 20, 2026